{"version":"1.0","provider_name":"Gobia Sverige","provider_url":"https:\/\/gobia.se\/se","author_name":"mkmedia","author_url":"https:\/\/gobia.se\/se\/author\/mkmedia\/","title":"Gobia Enterprises investerar i Thioredoxin Systems AB - Gobia Sverige","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"7cpwiOmdCt\"><a href=\"https:\/\/gobia.se\/se\/nyheter\/gobia-enterprises-investerar-i-thioredoxin-systems-ab\/\">Gobia Enterprises investerar i Thioredoxin Systems AB<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/gobia.se\/se\/nyheter\/gobia-enterprises-investerar-i-thioredoxin-systems-ab\/embed\/#?secret=7cpwiOmdCt\" width=\"600\" height=\"338\" title=\"\u201dGobia Enterprises investerar i Thioredoxin Systems AB\u201d &ndash; Gobia Sverige\" data-secret=\"7cpwiOmdCt\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/gobia.se\/se\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/gobia.se\/se\/wp-content\/uploads\/sites\/3\/2025\/02\/gobia-thx-systems.jpg","thumbnail_width":1067,"thumbnail_height":600,"description":"F\u00f6retagets patenterade antibiotikum, EbsArgent\u2122, utnyttjar en unik verkningsmekanism f\u00f6r att f\u00f6rb\u00e4ttra behandlingens effektivitet samtidigt som resistensutvecklingen minimeras. Denna innovation har potential att ta itu med en stor medicinsk utmaning, eftersom urinv\u00e4gsinfektioner blir allt sv\u00e5rare att behandla med befintliga antibiotika. Investeringen kommer att st\u00f6dja slutf\u00f6randet av prekliniska studier och initieringen av kliniska fas I-pr\u00f6vningar. Som en [&hellip;]"}